ProMetic Begins Trading on OTCQX(R)

ProMetic Life Sciences Inc. (TSX:PLI) (OTCQX:PFSCF), ("ProMetic" or the
"Corporation") announced today that its common shares have commenced trading on
OTCQX International under the symbol PFSCF. OTCQX International is a segment of
the OTCQX marketplace reserved for high-quality non-U.S. companies listed on a
qualified stock exchange in their home country. 


Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial
Services Inc. (NYSE MKT:LTS) will serve as ProMetic's Principal American Liaison
("PAL") on the OTCQX, responsible for providing professional guidance on the
OTCQX requirements. 


"More than 50% of our revenues come from U.S. clients and strategic partners;
this combined with our growing U.S. based subsidiary, the recent grant of an
orphan drug designation by the U.S. FDA as well as various upcoming US IND
filings has made it necessary to accommodate the growing demand for our
securities from U.S. based investors", mentioned Mr. Pierre Laurin, President
and Chief Executive Officer of ProMetic Life Sciences Inc. "Joining OTCQX fits
perfectly with our strategy to further develop our presence in the U.S.", added
Mr. Laurin.


ProMetic also announced today that its company information would be made
available via Standard & Poor's Corporation Records Listing Program. As part of
the program, a full description of ProMetic will be published in the Daily News
Section of Standard & Poors's Corporation Records, a recognized securities
manual for secondary trading in up to 38 States under the Blue Sky Laws.
Standard & Poor's Corporation Records is available in print, CD-ROM, and via the
web at www.netadvantage.standardandpoors.com as well as through numerous
electronic vendors. The company information about ProMetic to be made available
through this program includes an in-depth description of the ProMetic's business
operations, share price, dividend history, shares outstanding, company financial
position, earnings, and full income statement and balance sheet. 


About ProMetic Life Sciences Inc. 

ProMetic Life Sciences Inc. (www.prometic.com) is a global biopharmaceutical
company specializing in the design of small molecules that mimic unique and
specific interactions between proteins, research, development, manufacture and
marketing of a variety of commercial applications derived from its proprietary
Mimetic Ligand(TM) technology. This technology is used in large-scale
purification of biologics, drug development, proteomics and the elimination of
pathogens. ProMetic is also active in developing its own novel therapeutic
products targeting unmet medical needs in the field of fibrosis, anemia,
neutropenia, cancer and autoimmune diseases/inflammation as well as certain
nephropathies Headquartered in Laval (Canada), ProMetic has R&D facilities in
the UK, the U.S. and Canada, manufacturing facilities in the UK and business
development activities in the U.S., Europe and Asia. 


Forward Looking Statements 

This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks affect
our business, or if our estimates or assumptions turn out to be inaccurate. Such
risks and assumptions include, but are not limited to, ProMetic's ability to
develop, manufacture, and successfully commercialize value-added pharmaceutical
products, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability of ProMetic to
take advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in economic
conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current
expectations on page 26 of ProMetic's Annual Information Form for the year ended
December 31, 2012, under the heading "Risk and Uncertainties related to
ProMetic's business". As a result, we cannot guarantee that any forward-looking
statement will materialize. We assume no obligation to update any
forward-looking statement even if new information becomes available, as a result
of future events or for any other reason, unless required by applicable
securities laws and regulations. All amounts are in Canadian dollars unless
indicated otherwise. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Pierre Laurin
President and CEO
ProMetic Life Sciences Inc.
[e-mail]
+1.450.781.0115


Frederic Dumais
Director, Communications and Investor relations
ProMetic Life Sciences Inc.
[e-mail]
+1.450.781.0115